Compounds > phenyl acetate
Page last updated: 2024-08-23

phenyl acetate and pai 039

phenyl acetate has been researched along with pai 039 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Albornoz, F; Brown, NJ; Crandall, DL; Elokdah, H; Fogo, AB; Griffin, JP; Vaughan, DE; Weisberg, AD1
Antrilli, TM; Crandall, DL; Elokdah, H; Friedrichs, GS; Hennan, JK; Hreha, A; Ji, A; Leal, M; Morgan, GA; Swillo, RE1
Alessi, MC; Collen, D; Juhan-Vague, I; Lijnen, HR; Van Hoef, B1
Alessi, MC; Crandall, DL; El Ayachi, S; Hreha, AL; Juhan-Vague, I; Leik, CE; Quinet, EM; Savio, DA1
Correia, ML; Haynes, WG1

Reviews

1 review(s) available for phenyl acetate and pai 039

ArticleYear
A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI?
    Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:10

    Topics: Acetates; Animals; Humans; Indoleacetic Acids; Indoles; Obesity; Plasminogen Activator Inhibitor 1

2006

Other Studies

4 other study(ies) available for phenyl acetate and pai 039

ArticleYear
Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
    Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:2

    Topics: Acetates; Administration, Oral; Angiotensin II; Animals; Antigens, Differentiation; Aorta; Aortic Diseases; Blood Pressure; Chemokine CCL2; Collagen Type I; Collagen Type III; Drug Evaluation, Preclinical; Fibronectins; Fibrosis; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Heart; Hypertrophy, Left Ventricular; Indoleacetic Acids; Indoles; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nephrectomy; Osteopontin; Plasminogen Activator Inhibitor 1; Random Allocation; RNA, Messenger; Sialoglycoproteins; Single-Blind Method; Sodium Chloride, Dietary

2005
Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 314, Issue:2

    Topics: Acetates; Animals; Bleeding Time; Blood Pressure; Coronary Circulation; Coronary Thrombosis; Dogs; Endpoint Determination; Fibrinolysis; Fibrinolytic Agents; Heart Rate; Hemostasis; Indoleacetic Acids; Indoles; Partial Thromboplastin Time; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Ventricular Remodeling

2005
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:6

    Topics: Acetates; Adipose Tissue; Animals; Body Composition; Body Weight; Indoleacetic Acids; Indoles; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Plasminogen Activator Inhibitor 1

2005
Modulation of adipose tissue development by pharmacological inhibition of PAI-1.
    Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:10

    Topics: Acetates; Adipocytes; Adipose Tissue; Adult; Animals; Body Weight; Cell Count; Cell Differentiation; Cells, Cultured; Female; Glucose; Humans; Indoleacetic Acids; Indoles; Mice; Mice, Inbred C57BL; Organ Size; Plasminogen Activator Inhibitor 1; Stem Cells

2006